Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Operating Leases (2021 - 2025)

Vivos Therapeutics has reported Operating Leases over the past 5 years, most recently at $3.8 million for Q4 2025.

  • Quarterly Operating Leases rose 271.01% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, up 271.01% year-over-year, with the annual reading at $3.8 million for FY2025, 271.01% up from the prior year.
  • Operating Leases was $3.8 million for Q4 2025 at Vivos Therapeutics, up from $2.9 million in the prior quarter.
  • Over five years, Operating Leases peaked at $3.8 million in Q4 2025 and troughed at $641000.0 in Q4 2021.
  • The 5-year median for Operating Leases is $1.9 million (2024), against an average of $1.9 million.
  • The largest YoY upside for Operating Leases was 271.01% in 2025 against a maximum downside of 50.48% in 2025.
  • A 5-year view of Operating Leases shows it stood at $641000.0 in 2021, then soared by 211.08% to $2.0 million in 2022, then fell by 23.72% to $1.5 million in 2023, then tumbled by 31.95% to $1.0 million in 2024, then soared by 271.01% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Operating Leases are $3.8 million (Q4 2025), $2.9 million (Q3 2025), and $2.8 million (Q2 2025).